leisure time -WSS

leisure time

author：Wikipedia 2025-10-02 17:22:53 - browse：1498

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： With trial win, GSK could get blood cancer drug back on market

focus

hotspot

WSS

AMAs digital advisors table RPM coding reform proposal, again

Tome Biosciences co

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Having children helps parents live longer, especially after age 80

Innovation in antibiotics is ailing. 'Brain drain' may kill it

How to increase colonoscopy rates? Looks like an AI can help

focus

leisure time

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

What does generative AI mean for health care? We asked experts

HIV drugs protect against transmission, even in unprotected sex

Heart attack and stroke risk calculators need revising

ASCO: Palliative care found as helpful given virtually as in person

Jerome Adams on the need for new antivirals for Covid

ASCO: AstraZeneca says CAR

Hepatitis C has a cure — but many Americans still lack access to it

With trial win, GSK could get blood cancer drug back on market

knowledge

Shifting the focus from loneliness to social health

Juul documents reveal insider tactics on political lobbying

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Congress might make insulin pumps more accessible to the blind

Tome Biosciences co

BMI, flaws aside, is found to be useful estimate of body fat in youth

focus

focus

hotspot

hotspot